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Extent of Lymphadenectomy in Esophageal Cancer: How Many
Lymph Nodes Is Enough?
Luis J. Herrera, MD
Thoracic Surgery, M.D. Anderson Cancer Center Orlando, Orlando, FL
There is no question that presence of lymph node (LN)
metastasis in esophageal cancer is one of the most powerful
prognostic indicators. Multiple studies have demonstrated
that patients with lymph node metastasis have more
aggressive tumor biology, higher rates of locoregional and
distant recurrence, and hence, worse survival. Esophageal
cancer staging according to the sixth edition of the tumor–
node–metastasis (TNM) staging manual of the American
Joint Committee on Cancer (AJCC) uses only the location
of the involved LN or the distance from the primary tumor
for nodal disease staging (i.e., N1 versus M1a).
1 This
method tends to group patients with very different disease
burden and biologic behavior into a similar stage, resulting
in a less powerful staging system. More recent studies have
explored the impact of LN metastases further, and inves-
tigators seem to agree that it is not only a question of the
presence or absence of nodal disease, but more impor-
tantly, how many LN are involved with disease.
2,3 Rizk
and colleagues reported that the prognosis of patients after
esophagectomy worsens signiﬁcantly after four or more
lymph nodes have metastases, irrespective of T stage.
3 LN
subclassiﬁcation according to nodal groupings showed
differences in survival curves, and better prognostic strat-
iﬁcation can be obtained to facilitate treatment decisions.
The Worldwide Esophageal Cancer Collaboration has
reported with tremendous effort an international and multi-
institutional dataset that reﬁned the recommendations for
the revised esophageal cancer staging system and incor-
porates the important factor of extent of nodal disease.
4
After these and other studies highlighted the importance of
lymph node subclassiﬁcation, the upcoming seventh edi-
tion of the AJCC TNM staging manual has incorporated
these changes into a more robust esophageal cancer staging
system.
5 The new staging will have three groups of positive
nodal disease (N1, 1–2 regional LN; N2, 3–6 regional LN;
N3, more than 7 metastatic LN).
5 The need for more
detailed nodal analysis now puts the pressure on perform-
ing a thorough and adequate lymphadenectomy during
esophagectomy in order to ensure an accurate nodal stage,
but what is the optimal extent of lymphadenectomy for
esophageal cancer to ensure adequate LN clearance and
avoid understaging the disease? Does a more radical lym-
phadenectomy confer a survival advantage, or is the
improved survival an effect of stage migration? Is a more
radical lymphadenectomy also necessary in cases where
chemoradiation therapy is also administered?
In this issue of the Annals of Surgical Oncology, two
manuscripts investigate the survival impact of the extent or
adequacyoflymphadenectomyinesophagealsquamouscell
carcinoma and adenocarcinoma. The ﬁrst article is a large
retrospective study from China. Hu and colleagues evaluate
the inﬂuence of the number of dissected LN on the accuracy
of TNM staging and prognosis in esophageal squamous cell
carcinoma(ESCC).Thisisananalysisof1,098patientswho
underwent esophagectomy with LN dissection without use
of neoadjuvant therapy, over a 16-year period. Most of the
tumors were in the mid-esophagus, as expected (76%). The
median number of four LN removed was relatively low
compared with other series (range 1–24). The authors used a
cutoff of six removed LN as the deﬁnition of ‘‘adequate’’
nodaldissection.Theresultsshowedthatpatientswithsixor
more LN dissected had a higher rate of positive LN
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overall survival that was statistically signiﬁcant in patho-
logically node-negative (pN0) patients. This suggests that
the survival beneﬁt in patients with adequate LN dissection
could be related to stage migration. Furthermore, there was
no survival advantage in patients with pathologic LN
metastasis relating to whether more or fewer than six lymph
nodes were removed, suggesting that the lower survival for
patients with inadequate lymphadenectomy may be a result
of missed nodal involvement. It is interesting that, com-
paratively, the number of dissected LN is this study is lower
than in most other series, yet it was able to demonstrate a
difference in survival using a lower LN cutoff point.
Inthe secondstudy,Solomonandcolleaguesperformeda
cancer registry analysis of the Surveillance, Epidemiology,
and End Results (SEER) database, encompassing 4,224
patients with esophageal adenocarcinoma. The authors
included patients treated also with radiation therapy to
investigate whether multimodality therapy inﬂuenced the
effect of lymphadenectomy in the treatment of esophageal
cancer. The authors used a cutoff of more than 18 LN
removed to classify lymphadenectomy as ‘‘adequate’’ based
on previous available literature.
3 The authors report that
39% of patients had LN metastasis at time of surgery (pN1).
Interestingly, 82.1% of patients had\18 LN removed and
were classiﬁed as receiving inadequate lymphadenectomy.
The mean number of LN removed was 8.7. The majority of
patients (55.8%) did not receive radiation therapy, and only
29% received neoadjuvant therapy in this cohort. The
highest median survival time (MST) occurred in patients
who received adequate lymphadenectomy and were patho-
logically node negative. They described that node-negative
patients who received neoadjuvant radiation had worse
survival outcome, but this may account for more advanced
clinical stage and larger disease burden prior to therapy.
The authors found that, in addition to adequate lymphade-
nectomy, use of radiation therapy (assumed to be
chemoradiation) was an indicator of improved survival.
Interestingly, in patients with pathologic LN metastasis who
received neoadjuvant therapy, adequate lymphadenectomy
was important to achieve improved survival, implying that
adding another form of local therapy is not a substitute for
adequate lymphadenectomy in this retrospective study.
These articles highlight several important issues in the
surgical therapy of esophageal cancer. Certainly, it seems
that, across the board, there is room for improvement in
terms of lymph node yield during esophagectomy. As
described in these two studies, the overall majority of
patients did not undergo lymph node dissection that met the
proposed goal of dissected nodes. However, the number of
retrieved lymph nodes depends on multiple factors. From
the surgeon’s standpoint, the number of dissected lymph
nodes will depend on the surgical approach (transhiatal
versus transthoracic versus en bloc) and the number of
dissected ﬁelds. Surgeons who perform their own nodal
dissection of the specimen at the back table or submit
individual packets of lymph nodes according to nodal sta-
tions will tend to obtain higher number of nodes, as noted in
a recent multi-institutional trial.
6 From a pathological
standpoint, the task of lymph node retrieval can be tedious,
and often pathologists are too busy to perform an exhaustive
search. At times this task is delegated to a junior pathology
resident to be performed on a formalin-ﬁxed specimen
instead of a fresh specimen. Therefore, maximizing nodal
retrieval for accurate staging is a collaborative effort
between surgeons and pathologists. Institutional protocols
can be implemented so that both surgeons and pathologists
can maximize nodal yield. Cases where the nodal count
seems low should prompt repeat examination of the speci-
men by an experienced pathologist to look for more LN, or
review by the surgeon to determine whether technique
modiﬁcations are warranted in subsequent cases.
Several questions remain. What is the optimal number
of lymph nodes to classify an esophagectomy as adequate?
Based on the available literature in both ESCC and ade-
nocarcinoma, some authors recommend anywhere from 12
to 23 LN as the appropriate cutoff for ‘‘adequate’’ lym-
phadenectomy. The upcoming esophageal cancer staging in
the AJCC staging manual recommends resection of as
many lymph nodes as possible and that more nodes should
be dissected with increasing pT stage ( C 10 for T1; C 20
for T2; and C 30 for T3 and T4) based on worldwide data.
5
Certainly, sufﬁcient nodal clearance should be performed
to comfortably rule out missed nodal disease.
If nodal clearance is so important, should a more
aggressive operation or adding a cervical ﬁeld become
standard for locally advanced esophageal cancer? Is the
survival advantage of more radical operations a direct
beneﬁt or the effect of stage migration? In a prospective
randomized trial comparing transhiatal (THE) versus
transthoracic en bloc (TTE) esophagectomy, Hulscher and
colleagues noted a much higher mean number of dissected
LN (31 versus 16) and reported a trend towards improved
survival, although it did not reach statistical signiﬁcance.
7
Several surgical series have reported even higher number of
dissected LN with improvement in survival even in patients
with multiple LN metastases, but an increase in morbidity
andpossiblyinmortalityarefrequentlyunavoidableinmore
radical operations.
8 Whether a more aggressive en bloc or
routine three-ﬁeld lymphadenectomy is a better esophageal
cancer operation, or whether the number of dissected lymph
nodes is the factor that impacts survival regardless of the
technique, will require further investigation. Despite
improved staging with more extensive lymphadenectomy
and better locoregional control, the true impact on survival
is still controversial, in part due to the effect of stage
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studies will be needed to clarify this question.
As an alternative or in addition to more radical esoph-
ageal resections, many centers around the United States
use neoadjuvant chemoradiation (CRT) for multimodality
therapy for locally advanced (stage IIa–IVa) esophageal
cancer, although the trials supporting this approach have
many limitations. Despite this, this trimodality approach
has dramatically reduced locoregional failures and has
been shown to achieve pathological downstaging in a sig-
niﬁcant number of patients, resulting in improved
prognosis. However, does the addition of CRT as another
form of locoregional control impact the need for extended
resections and a large LN retrieval? Pathologic response
(pP) to neoadjuvant therapy has been shown to be a pow-
erful prognostic indicator after esophagectomy. Patients
with complete (P0) or near-complete (P1) response have
been shown to have markedly improved prognosis. Swisher
and colleagues have proposed another modiﬁcation to the
staging system to account for response to neoadjuvant
therapy.
9 With the current data, it is unclear whether the
same requirements in terms of number of LN for improved
staging and survival apply in the setting of CRT. Most
studies evaluating the survival effect of the number of
resected LN exclude patients who received neoadjuvant
therapy.
Given the results reported in these studies as well as
others in the literature, a more standardized method of
lymph node dissection for esophageal cancer is needed, as
proposed in the new seventh edition of the AJCC TNM
staging manual. From the surgeon’s standpoint, regardless
of the surgical approach or planned extent of lymphade-
nectomy, an effort should be made to resect as many
regional LN as possible, as long as the resultant morbidity is
acceptable. Collaboration between surgeons and pathologist
to establish institutional protocols to maximize lymph node
retrieval is essential. With more accurate staging and the
application of a more robust staging system, future studies
will be needed to further support the best approach to
maximize locoregional control and survival in esophageal
cancer.
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